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Mesenchymal stem cells (MSCs) raise high hopes for regener-
ative medicine—in fact, they have already paved their way to
a large number of clinical trials for a broad range of diseases.
So far, several studies provided promising results, but this
relatively new area of research requires further validation as
some of the studies revealed varying outcomes. This might be
a result of the heterogeneity of MSC cultures and absence of
reliable protocols for isolation of the naı¨ve stem cell fraction.
MSCs are not precisely defined on a molecular level. They
can be isolated from many tissues under diﬀerent culture
conditions—yet, they comprise multiple subpopulations and
only a subset reveals multipotent diﬀerentiation capacity into
at least adipogenic, chondrogenic, and osteogenic lineages.
Notably, the composition of subpopulations seems to be
greatly aﬀected by culture methods and in the course of
culture expansion.
Culture of MSCs has already been established in the
early 1960s when fibroblastoid cells were discussed as sup-
portive stromal cells within the hematopoietic bone marrow
niche. Initially, application of MSCs in regenerative settings
was mainly based on the hope to cure diseases or defects
of cartilage, bone, or adipogenic tissue. Their use for mus-
culoskeletal diseases still remains one of the most frequent
applications (Figure 1). Particularly in an autologous setting,
diﬀerentiated derivatives of MSCs may be functionally
integrated in constructs to enhance regeneration of bone or
cartilage defects.
There is a growing perception that MSCs reveal addi-
tional attributes which open further clinical perspectives:
they seem to secrete active molecules which are capable to
stimulate regeneration. The precise nature of these mole-
cules, for example, growth factors, microvesicles, or direct
cell-cell interaction, needs to be further specified. Yet, this
stimulatory paracrine function may contribute to beneficial
eﬀects in applications such as ischemia, liver, and heart dis-
eases. Furthermore, several studies have demonstrated that
human MSCs reduce allorecognition, interfere with den-
dritic cell and T-cell function, and generate a local immuno-
suppressive microenvironment by secreting cytokines. This
immunomodulatory function paved the way for cellular
therapy in autoimmune diseases such as systemic lupus ery-
thematosus, multiple sclerosis, or Crohns disease. Prelimi-
nary results with MSCs are promising for the treatment of
graft-versus-host disease (GVHD) after allogeneic hematop-
oietic stem cell transplantation.
Although we are only starting to understand the mech-
anism of repair, the ease of culture isolation of MSCs, their
moderate side eﬀects in ongoing trials, and their pleiotropic
functions make them good candidates for cellular therapy.
There is an urgent need for further randomized, double-
blinded, placebo-controlled clinical trials to unequivocally
demonstrate safety and eﬃcacy of MSCs. These results will
also feedback on basic research to optimize culture con-
ditions and cell preparations for a given application. This
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Figure 1: MSCs in clinical trials. 252 trials have been registered
at http://www.clinicaltrials.gov/ (including 46 in North America,
61 in Europe, and 92 in East Asia, assessed on 11/20/2012). MSCs
are tested for a broad range of diseases, and selected categories are
presented.
special issue summarizes review papers and clinical trials to
provide insight in clinical perspectives of MSCs.
Several methods for isolation of MSCs from human
bone marrow (BM) have been described: they are commonly
isolated from the mononuclear cell fraction upon density
gradient centrifugation. Alternatively, MSCs can be isolated
by direct plating of BM. K. Mareschi and coworkers have
compared these isolation regimens in “multipotent mesenchy-
mal stromal stem cell expansion by plating whole bone marrow
at a low cellular density: a more advantageous method for
clinical use”. The results demonstrate that plating of whole
bone marrow provides a suitable alternative for isolation of
MSCs with relatively little hematopoietic contamination and
slightly longer telomeres at first passage. Furthermore, the
authors have addressed the impact of seeding density. Over-
all, this study supports the notion that MSCs have a diverse
repertoire of distinct subpopulations which need to be taken
into account.
Alternatively, MSCs can also be isolated from adipose
tissue (AT). These cells play a role in autologous lipotransfer
for soft tissue reconstruction, and they can also be culture
isolated. The anatomical location and the harvesting method
may influence AT-MSCs and this has been addressed by M.
Aguena and coworkers in “Optimization of parameters for a
more eﬃcient use of adipose-derived stem cells in regenerative
medicine therapies”: comparison of samples from the lower
abdomen versus flank revealed a significantly higher number
of nucleated cells and expression of MSC markers in samples
from the abdomen. Comparison of either pump-assisted
liposuction or manual lipoaspiration did not aﬀect cell
numbers. These results exemplify the crucial role of starting
material and cell isolation methods.
BM-derivedMSCs have been described now over decades
with regard to their osteogenic capacity. In this issue E.
Zomorodian and M. Eslaminejad give an actual overview
about “Mesenchymal stem cells as a potent cell source for bone
regeneration”. First, the authors give a short summary about
MSC from diﬀerent tissues. But regardless of which source,
osteogenic diﬀerentiation of MSC in vitro always has to
be induced by inductive factors. Although many exogenous
osteoinductive reagents have been described, sometimes the
specific molecular pathways by which the cellular diﬀeren-
tiation processes are modulated still need to be clarified. In
addition, a better understanding of the in vivo migration of
MSC to defect sites might improve their therapeutic use for
bone repair strategies in the future. Another future prospect
might be the application of MSC as vehicles for bone gene
therapy, but also in this field many issues have to be solved.
M. Mazo and colleagues review in “Mesenchymal stem
cells and cardiovascular disease: a bench to bedside roadmap”
the promising actions of MSC on injured myocardium
by paracrine activity as well as diﬀerentiation into car-
diovascular cell lineages. This comprehensive review paper
demonstrates advantages of cellular therapy. However, the
authors also point out that there are still many open
questions at the level of basic research and animal models
as well as even more at the outcome of clinical studies.
N. Venkataramana and coworkers have demonstrated in
“Bilateral transplantation of allogenic adult human bone
marrow-derived mesenchymal stem cells into the subven-
tricular zone of parkinson’s disease: a pilot clinical study”
the safety of the procedure in 12 patients one year after the
intervention. The authors assume beneficial neuroprotective
and neurorestorative eﬀects ofMSCs. However, mixed results
were obtained in this study, and only some patients showed a
clinical improvement. This might be due to the fact that the
duration of the disease varied widely in the study group. In
addition, profound diﬀerences in the observed cell properties
were mentioned, although the MSCs were only isolated from
three diﬀerent donors. Again, this clarifies that more basic
work has to be done to enable a better definition of MSC
(sub-) populations for a stable and reliable transplantation
procedure in clinical settings.
MSCs mediate immunomodulatory eﬀects. It might be
possible that not only one subset of naı¨ve stem cells but
almost all mesenchymal stromal cells exhibit this immuno-
genic capacity. For example it has been demonstrated that
mesenchymal stromal cells in general inhibit T-cell func-
tion. The development of GVHD is caused by T-cell reac-
tivity. Kuzmina and coworkers contribute to this issue with
the paper “Multipotent mesenchymal stromal cells for the
prophylaxis of acute graft-versus-host disease: a phase ii study”.
In this clinical study 19 patients received the standard GVHD
prophylaxis with immunosuppresive in combination with
the infusion of the MSCs of the hematopoietic stem cell
donor during leucocyte recovery by activation of the hema-
topoietic transplant. This group was compared to 19 patients
who were treated with the GVHD standard prophylaxis
alone. In the MSC group only one patient developed acute
GVHD, while in the standard group 6 patients suﬀered
from this life-threatening disease. No diﬀerences in the graft
rejection rates or in the incidence of infections were observed
in both groups. But the overall mortality was 22.2% in the
standard prophylaxis group compared to 5.3% in the MSC-
treated group.
Taken together, MSCs provide promising perspectives
for clinical applications with enormous potential for devel-
opment, but the definite areas of application need to be
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further specified and validated. At the same time, a better
molecular understanding is required for quality control and
standardization of cellular therapeutics.
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